{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T10:55:52Z","timestamp":1791284152908,"version":"4.1.0"},"reference-count":52,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T00:00:00Z","timestamp":1768348800000},"content-version":"vor","delay-in-days":13,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["J Deutsche Derma Gesell"],"published-print":{"date-parts":[[2026,1]]},"abstract":"<jats:title>Summary<\/jats:title>\n                  <jats:p>This first part of the updated German S3 guideline on the treatment of psoriasis vulgaris covers the sections on treatment recommendations, treatment goals, and monitoring of therapies. The recommendations are based on the current Cochrane network meta\u2010analysis, the results of which are also summarized. When selecting systemic therapies for psoriasis vulgaris, the guideline emphasizes consideration of efficacy, safety, comorbidities, and individual patient factors. The decision framework is presented in the treatment options overview, and in this updated version, the possibility of first\u2010line therapy with biologics or novel targeted small molecules is more prominently highlighted. Standardized instruments for assessing disease severity, as well as patient\u2010centered treatment goals, are underscored. A Psoriasis Area and Severity Index (PASI) 75 response is defined as the minimum therapeutic target, while PASI 90 or an absolute PASI &lt;2 are considered desirable goals. Since the last version, two newly approved agents, bimekizumab and deucravacitinib, have been incorporated, accompanied by specific usage recommendations. Among the established therapies, guidance on methotrexate has been extensively revised, particularly regarding administration, dosing, and monitoring. This guideline aims to provide clinicians with an evidence\u2010based framework for therapy selection and monitoring, while strengthening shared decision\u2010making with patients.<\/jats:p>","DOI":"10.1111\/ddg.16002","type":"journal-article","created":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T08:53:36Z","timestamp":1768380816000},"page":"122-137","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["S3 Guideline for the treatment of psoriasis vulgaris, adapted from EuroGuiDerm \u2013 part 1: Treatment recommendations and monitoring"],"prefix":"10.1111","volume":"24","author":[{"given":"Alexander","family":"Nast","sequence":"first","affiliation":[{"name":"Division of Evidence\u2010Based Medicine (dEBM) Department of Dermatology Venereology and Allergology Charit\u00e9 \u2013 Universit\u00e4tsmedizin Berlin corporate member of Freie Universit\u00e4t Berlin and Humboldt\u2010Universit\u00e4t zu Berlin  Berlin Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Altenburg","sequence":"additional","affiliation":[{"name":"Department of Dermatology Venereology and Allergology Dessau Municipal Hospital  Dessau Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4026-8728","authenticated-orcid":false,"given":"Matthias","family":"Augustin","sequence":"additional","affiliation":[{"name":"Institute for Health Services Research in Dermatology and Nursing (IVDP) University Medical Center Hamburg\u2010Eppendorf (UKE) Hamburg Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Bachmann","sequence":"additional","affiliation":[{"name":"Dermatology Center Berlin Siddi &amp; Bachmann  Berlin Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolf\u2010Henning","family":"Boehncke","sequence":"additional","affiliation":[{"name":"Service de Dermatologie et V\u00e9n\u00e9r\u00e9ologie H\u00f4pitaux Universitaires de Gen\u00e8ve  Geneva Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Cornberg","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology Hepatology and Endocrinology Hannover Medical School  Hannover Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hilte","family":"Geerdes\u2010Fenge","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Tropical Medicine and Infectious Diseases Rostock University Medical Center Rostock Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brit","family":"H\u00e4cker","sequence":"additional","affiliation":[{"name":"German Central Committee against Tuberculosis (DZK)  Berlin Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"H\u00e4rle","sequence":"additional","affiliation":[{"name":"Rheumatology Center in conformity with G\u2010BA Department of Rheumatology Clinical Immunology and Physical Therapy Marienhaus Hospital Mainz  Mainz Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joachim","family":"Klaus","sequence":"additional","affiliation":[{"name":"German Psoriasis Federation  Hamburg Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michaela","family":"K\u00f6hm","sequence":"additional","affiliation":[{"name":"Division of Rheumatology Immunology \u2013 Inflammation Medicine University Hospital Frankfurt Goethe University  Frankfurt am Main Germany"},{"name":"Fraunhofer Institute for Translational Medicine and Pharmacology ITMP Frankfurt  Frankfurt am Main Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arno","family":"K\u00f6llner","sequence":"additional","affiliation":[{"name":"Dermatology Office  Duisburg Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9539-0712","authenticated-orcid":false,"given":"Ulrich","family":"Mrowietz","sequence":"additional","affiliation":[{"name":"Psoriasis Center Department of Dermatology Venereology Allergology University Hospital Schleswig\u2010Holstein Campus Kiel  Kiel Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans\u2010Michael","family":"Ockenfels","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Allergy Hospital Hanau  Hanau Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonia","family":"Pennitz","sequence":"additional","affiliation":[{"name":"Division of Evidence\u2010Based Medicine (dEBM) Department of Dermatology Venereology and Allergology Charit\u00e9 \u2013 Universit\u00e4tsmedizin Berlin corporate member of Freie Universit\u00e4t Berlin and Humboldt\u2010Universit\u00e4t zu Berlin  Berlin Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Philipp","sequence":"additional","affiliation":[{"name":"Dermatology Office  Oranienburg Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Richter","sequence":"additional","affiliation":[{"name":"Helios Versorgungszentren GmbH MVZ Gotha  Gotha Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Rosenbach","sequence":"additional","affiliation":[{"name":"Dermatology Office  Osnabr\u00fcck Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom","family":"Schaberg","sequence":"additional","affiliation":[{"name":"German Central Committee against Tuberculosis (DZK)  Berlin Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Schlaeger","sequence":"additional","affiliation":[{"name":"Dermatology Office  Oldenburg Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerhard","family":"Schmid\u2010Ott","sequence":"additional","affiliation":[{"name":"Berolina Hospital  L\u00f6hne Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Sebastian","sequence":"additional","affiliation":[{"name":"Dermatology Office  Mahlow Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karisa","family":"Th\u00f6lken","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Allergology University Hospital Augsburg  Augsburg Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralph","family":"von Kiedrowski","sequence":"additional","affiliation":[{"name":"Dermatology Office  Selters Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uwe","family":"Willuhn","sequence":"additional","affiliation":[{"name":"German Psoriasis Federation  Hamburg Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3355-8663","authenticated-orcid":false,"given":"Christoph","family":"Zeyen","sequence":"additional","affiliation":[{"name":"Division of Evidence\u2010Based Medicine (dEBM) Department of Dermatology Venereology and Allergology Charit\u00e9 \u2013 Universit\u00e4tsmedizin Berlin corporate member of Freie Universit\u00e4t Berlin and Humboldt\u2010Universit\u00e4t zu Berlin  Berlin Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,1,14]]},"reference":[{"key":"e_1_2_12_2_1","doi-asserted-by":"publisher","DOI":"10.1159\/000250839"},{"key":"e_1_2_12_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-3083.2009.03562.x"},{"key":"e_1_2_12_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.15537"},{"key":"e_1_2_12_5_1","unstructured":"World Health Organization.WHO\u2010Five well\u2010being index.1998. Available from:https:\/\/www.psykiatri\u2010regionh.dk\/who\u20105\/Pages\/default.aspx[Last accessed June 27 2024]."},{"key":"e_1_2_12_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.17434"},{"key":"e_1_2_12_7_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00403-010-1080-1"},{"key":"e_1_2_12_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2010.04.026"},{"key":"e_1_2_12_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2010.09.011"},{"key":"e_1_2_12_10_1","unstructured":"The GRADE Working Group. Available from:http:\/\/www.gradeworkinggroup.org\/[Last accessed July 10 2025]."},{"key":"e_1_2_12_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.13995"},{"key":"e_1_2_12_12_1","article-title":"Systemic pharmacological treatments for chronic plaque psoriasis: a network meta\u2010analysis","author":"Sbidian E","year":"2023","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_2_12_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2024.09.012"},{"key":"e_1_2_12_14_1","unstructured":"Biogen GmbH.Informationsschreiben des Unternehmens Biogen GmbH zur Einstellung der Produktion und des Vertriebs von Fumaderm\u00ae initial und Fumaderm\u00ae (Wirkstoffe: Dimethylfumarat\/Ethylhydrogenfumarat).2024. Available from:https:\/\/www.bfarm.de\/SharedDocs\/Arzneimittelzulassung\/Lieferengpaesse\/DE\/2024\/info_Dimethylfumarat_Ethylhydrogenfumarat_10241206.pdf?__blob=publicationFile[Last accessed December 18 2024]."},{"key":"e_1_2_12_15_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0221823"},{"key":"e_1_2_12_16_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-022-06221-z"},{"key":"e_1_2_12_17_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11926-023-01116-7"},{"key":"e_1_2_12_18_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.24034"},{"key":"e_1_2_12_19_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2014-205228"},{"key":"e_1_2_12_20_1","unstructured":"Arzneimittelkommission der deutschen \u00c4rzteschaft (Akd\u00c4).Methotrexat: Ma\u00dfnahmen zur Vermeidung von Dosierungsfehlern mit potenziell t\u00f6dlichen Folgen bei der Anwendung von Methotrexat bei Autoimmunerkrankungen. Rote\u2010Hand\u2010Brief vom 25.11.2019.2019. Available from:https:\/\/www.akdae.de\/fileadmin\/user_upload\/akdae\/Arzneimittelsicherheit\/RHB\/Archiv\/2019\/20191125.pdf[Last accessed May 06 2024]."},{"key":"e_1_2_12_21_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2022.0434"},{"key":"e_1_2_12_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-3083.2010.03932.x"},{"key":"e_1_2_12_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2022.12.034"},{"key":"e_1_2_12_24_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-021-05678-8"},{"key":"e_1_2_12_25_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-023-06847-7"},{"key":"e_1_2_12_26_1","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.211281"},{"key":"e_1_2_12_27_1","doi-asserted-by":"publisher","DOI":"10.1055\/a-1880-2283"},{"key":"e_1_2_12_28_1","article-title":"Risk of Liver Fibrosis in Methotrexate\u2010Treated Patients: A Systematic Review","volume":"14","author":"Bichenapally S","year":"2022","journal-title":"Cureus"},{"key":"e_1_2_12_29_1","doi-asserted-by":"publisher","DOI":"10.4254\/wjh.v15.i5.699"},{"key":"e_1_2_12_30_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780390214"},{"key":"e_1_2_12_31_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-016-3398-3"},{"key":"e_1_2_12_32_1","doi-asserted-by":"publisher","DOI":"10.1038\/ki.2010.483"},{"key":"e_1_2_12_33_1","doi-asserted-by":"publisher","DOI":"10.1038\/ki.2011.310"},{"key":"e_1_2_12_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/0190-9622(93)70069-6"},{"key":"e_1_2_12_35_1","article-title":"Folic acid and folinic acid for reducing side effects in patients receiving methotrexate for rheumatoid arthritis","author":"Ortiz Z","year":"2000","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_2_12_36_1","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(200107)44:7<1515::AID-ART273>3.0.CO;2-7"},{"key":"e_1_2_12_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00126-4"},{"key":"e_1_2_12_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00125-2"},{"key":"e_1_2_12_39_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2102388"},{"key":"e_1_2_12_40_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2102383"},{"key":"e_1_2_12_41_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2022.1185"},{"key":"e_1_2_12_42_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/civ933"},{"key":"e_1_2_12_43_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.18954"},{"key":"e_1_2_12_44_1","unstructured":"GrollAH BuchheidtD HeinzW et\u00a0al.S1\u2010Leitlinie Diagnose und Therapie von Candida Infektionen: Gemeinsame Empfehlungen der Deutschsprachigen Mykologischen Gesellschaft (DMykG) und der Paul\u2010Ehrlich\u2010Gesellschaft f\u00fcr Chemotherapie (PEG) 2020. Available from:https:\/\/register.awmf.org\/de\/leitlinien\/detail\/082\u2010005[Last accessed January 03 2025]."},{"key":"e_1_2_12_45_1","unstructured":"European Medicines Agency.Sotyktu: EPAR \u2013 Product Information. Available from:https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/sotyktu[Last accessed September 26 2023]."},{"key":"e_1_2_12_46_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2022.07.002"},{"key":"e_1_2_12_47_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2022.08.061"},{"key":"e_1_2_12_48_1","unstructured":"Bristol Myers Squibb.SOTYKTU\u2122 (deucravacitinib) tablets for oral use: US prescribing information.2022. Available from:https:\/\/packageinserts.bms.com\/pi\/pi_sotyktu.pdf[Last accessed February 01 2023]."},{"key":"e_1_2_12_49_1","doi-asserted-by":"crossref","unstructured":"WarrenRB SofenH ImafukuS.Deucravacitinib long\u2010term efficacy and safety in plaque psoriasis: 2\u2010year results from the phase 3 POETYK PSO program. presented at: Presented at European Academy of Dermatology and Venereology (EADV) Spring Symposium; May 12\u201314 2022 2022;Ljubljana Slovenia.","DOI":"10.1136\/annrheumdis-2022-eular.2445"},{"key":"e_1_2_12_50_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-021-00596-8"},{"key":"e_1_2_12_51_1","doi-asserted-by":"publisher","DOI":"10.1002\/acr.24893"},{"key":"e_1_2_12_52_1","doi-asserted-by":"publisher","DOI":"10.1111\/cts.13435"},{"key":"e_1_2_12_53_1","unstructured":"European Medicines Agency.Uzpruvo: EPAR \u2013 Product Information.2024. Available from:https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/uzpruvo[Last accessed June 25 2024]."}],"container-title":["JDDG: Journal der Deutschen Dermatologischen Gesellschaft"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ddg.16002","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/ddg.16002","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ddg.16002","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T08:15:14Z","timestamp":1780474514000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ddg.16002"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":52,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["10.1111\/ddg.16002"],"URL":"https:\/\/doi.org\/10.1111\/ddg.16002","archive":["Portico"],"relation":{},"ISSN":["1610-0379","1610-0387"],"issn-type":[{"value":"1610-0379","type":"print"},{"value":"1610-0387","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"2025-09-23","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-09-24","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-01-14","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}